<button id="eiezk"><video id="eiezk"></video></button>
      <fieldset id="eiezk"></fieldset>
      <acronym id="eiezk"><small id="eiezk"></small></acronym>
    1. <dl id="eiezk"><dfn id="eiezk"><meter id="eiezk"></meter></dfn></dl>
      <acronym id="eiezk"><address id="eiezk"></address></acronym>
        <source id="eiezk"><pre id="eiezk"></pre></source>

        產(chǎn)品名稱 iLite? ADCC Target HER2 (-) Assay Ready Cells from EAGLE BIOSCIENCES INC.
        產(chǎn)品貨號(hào) BM4016
        產(chǎn)品價(jià)格 現(xiàn)貨詢價(jià),電話:010-67529703
        產(chǎn)品規(guī)格 250 ul
        產(chǎn)品品牌 EAGLE BIOSCIENCES INC.
        產(chǎn)品概述
        產(chǎn)品詳情
        Edit&nbsp
        Product NameiLite? ADCC Target HER2 (-) Assay Ready Cells
        DescriptionThe iLite? ADCC Target HER2 (-) Assay Ready Cells can be used together with iLite? ADCC Effector (V) and iLite? ADCC Target HER2 (+) Assay Ready Cells for the quantification ADCC activity. ? Antibody-dependent cell-mediated cytotoxicity (ADCC) is a mechanism whereby pathogenic cells are lysed by lymphocytes, most often Natural Killer (NK) cells. The mechanism involves binding of antibodies to surface antigens on the pathogen. Crosslinking of these antibodies to NK cells through the binding of the Fc-portion to Fc receptors on the NK cells leads to activation of the NK cell and formation of an immune synapse with the pathogenic cell. The NK cell releases cytotoxic granules containing granzymes and perforin into the synapse, leading to apoptosis of the targeted cell. Breast cancer is the most common cancer in women worldwide, and the second most common cancer overall. Survival rates have improved in the recent years, and stratification of patients into subgroups has vastly improved treatment options for many patients. As an example, patients with HER2 positive breast cancer generally have a poor prognosis, but treatment with trastuzumab, a monoclonal antibody targeting the HER2 receptor, has shown to increase both overall survival and disease free survival when given together with chemotherapy. Trastuzumab's mechanism of action is mediated in part by inducing ADCC when crosslinking HER2 positive cells with the patient's immune cells. The drug was FDA approved for treatment of breast cancer patients in 1998, and many biosimilars are currently in development.
        Size250 ul
        Concentrationn/a
        ApplicationsRUO
        Other Namesn/a
        Gene, Accession, CAS #n/a
        Catalog #BM4016
        Price
        Order / More InfoiLite&reg; ADCC Target HER2 (-) Assay Ready Cells from EAGLE BIOSCIENCES INC.
        Product Specific Referencesn/a
        產(chǎn)品資料
        <button id="eiezk"><video id="eiezk"></video></button>
            <fieldset id="eiezk"></fieldset>
            <acronym id="eiezk"><small id="eiezk"></small></acronym>
          1. <dl id="eiezk"><dfn id="eiezk"><meter id="eiezk"></meter></dfn></dl>
            <acronym id="eiezk"><address id="eiezk"></address></acronym>
              <source id="eiezk"><pre id="eiezk"></pre></source>

              男人操女人在线观看,另类三区,阿v视频免费观看 | 久久中文网,欧美黄色1级视频,www.奇米影视 | 草草久久久亚洲AV成人,波多野结衣中文字幕一区,国产精品久久久久久久久久不蜜月 | 91视频网址,日韩三级大片,亚洲精品粉嫩小泬18p图片 | 中国美女一级特黄大片片,揉我胸啊嗯~出水了动漫,草逼91 | 亚洲欧洲小说图片在线免费观看,欧美美女被c,三级小说 | 曰韩在线视频,《诱人的乳》电影,日本女人喷水 | 女警花A∨毛片一区二区,国产成人无码视频在线观看,18禁污网站 | 两根粗大视频黑人,国产人久久人人人人爽,天天插日日插 | 国产乱婬AAAA片视频,啊轻点灬太粗嗯太深了啊柳岩,国产毛片一区二区三区 |